Tilagliptin impurity and preparation method thereof
By reacting in potassium carbonate and water and further processing in ethanol hydrochloric acid solution, the shortcomings of impurity preparation methods in the prior art are solved, and the preparation of ticagliptin impurities with high purity and high yield is achieved, which improves the quality control of drugs Accurate positioning and qualitative.
Patent Information
- Application Number
- CN202411141732.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-22
AI Technical Summary
The impurities produced when preparing key intermediates of ticagliptin in the prior art have an impact on the safety and effectiveness of the drug, but lack economical, fast, easy to operate and simple post-treatment methods, which affect drug quality control.
Potassium carbonate and water are used as medium, and the reaction in formula 1 and formula 2 in potassium carbonate and water to form formula 3, and then react in ethanol hydrochloric acid to obtain high-purity impurity compound 4, and the reaction in water reduces by-products The production of the product improves yield and purity.
The preparation of impurity formula 4 compounds with high purity and high yield is achieved, which simplifies operation, reduces costs, and improves the accurate positioning and qualitativeness of drug quality control. It is suitable for the detection and analysis of finished products of ticagliptin.
Smart Images

Figure CN118994016A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an impurity of tenegliptin and a preparation method thereof, belonging to the technical field of drug intermediate synthesis. Background Art
[0002] Teneligliptin is used to treat type II diabetes. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Mitsubishi Tanabe Pharma Co., Ltd. of Japan. The drug was approved for marketing in Japan in September 2011 and in China on August 6, 2021. 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine is a key intermediate of Teneligliptin, and its structure is shown in the figure below:
[0003]
[0004] The compound of formula 1 has attracted much attention as a key intermediate of teneligliptin. Since most impurities in drugs have potential toxicity and biological activity, the determination of impurities is crucial to the safety evaluation of drugs and can affect the safety and efficacy of drugs. Therefore, the preparation and control of impurities is an important part of the quality control of chemical drugs.
[0005] However, most of the methods for preparing the key intermediate compound of formula 1 of tenegliptin in the prior art will produce impurities as shown in formula 4 below, such as the method of patent CN105418507A;
[0006]
[0007] Researchers found that the impurity compound of formula 4 produced during the synthesis of the key intermediate compound of formula 1 will be derived into the raw material drug tenegliptin, which has a crucial impact on the safety and effectiveness of the final drug. Therefore, the control of the impurity of this intermediate will be one of the key factors in the preparation of high-quality tenegliptin products. In the process of drug development, the quality control of intermediates is an important link. The establishment of quality standards requires a certain amount of reference materials, so the development of the preparation method of the impurity compound of formula 4 is an important task in drug research.
[0008] There is no report on the preparation method of the impurity compound of formula 4 in the prior art, so there is an urgent need for a synthesis method of the impurity compound of formula 4 that is economical, fast, easy to operate, simple to post-process, high in yield and high in purity. At the same time, the high-purity and high-quality compound of formula 4 can be compared with the impurities in the product in the actual production process, thereby improving the accurate positioning and qualitative analysis of the impurities in the key intermediate compound of formula 1 of tenegliptin and the finished product of tenegliptin, which is conducive to strengthening the control of the impurity, improving the quality of the drug, and benefiting the patients who take the drug. Summary of the invention
[0009] In order to solve the above technical problems, the present invention provides an impurity of tenegliptin and a preparation method thereof. The method has simple operation, mild conditions, high yield, simple post-treatment and high purity, and is used for the research of impurity standards.
[0010] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions:
[0011] The present invention provides a method for preparing a key intermediate impurity compound of formula 4 of tenegliptin, and the reaction is as follows:
[0012]
[0013] The following steps are involved:
[0014] Step 1: reacting a compound of formula 1 with a compound of formula 2 in the presence of potassium carbonate and water to obtain a compound of formula 3;
[0015] Step 2: The compound of formula 3 is reacted in a hydrochloric acid ethanol solution to obtain a compound of formula 4.
[0016] As a further improvement of the present invention, including but not limited to, the molar ratio of the compound of formula 1 to the compound of formula 2 in step 1 is 1:(1-3), preferably 1:(1.1-2.5);
[0017] As a further improvement of the present invention, including but not limited to, the molar ratio of the compound of formula 1 to potassium carbonate in step 1 is 1:(1-5), preferably 1:(1.2-4);
[0018] As a further improvement of the present invention, including but not limited to, the reaction temperature in step 1 is 80 to 110° C., preferably 85 to 110° C.;
[0019] As a further improvement of the present invention, including but not limited to, the reaction time in step 1 is 5 to 24 hours, preferably 5 to 16 hours;
[0020] As a further improvement of the present invention, including but not limited to, the volume ml of the aqueous solution in step 1 is 1 to 20 times the mass g of the compound of formula 1, preferably 5 to 12 times;
[0021] As a further improvement of the present invention, in certain embodiments, after the reaction of step 1 is completed, the reaction solution is cooled to room temperature, and then an organic solvent and an acid are added, followed by extraction, separation, and concentration to dryness to obtain compound 3;
[0022] As a further improvement of the present invention, including but not limited to, the above-mentioned organic solvent includes one of ethyl acetate and dichloromethane;
[0023] As a further improvement of the present invention, including but not limited to, the above acid includes one or more of hydrochloric acid, sulfuric acid, and ethyl hydrochloride, such as 1N hydrochloric acid solution.
[0024] The method described in the first method of the present invention is carried out in water, which is more environmentally friendly than similar reactions in the prior art using organic solvents, and has higher yield and purity than preparation in organic solvents, better product quality, and is also conducive to post-processing.
[0025] As a further improvement of the present invention, including but not limited to, the molar ratio of hydrochloric acid in the hydrochloric acid ethanol solution of the compound of formula 3 in step 2 is 1:(1-20), preferably 1:(2-15);
[0026] As a further improvement of the present invention, including but not limited to, the reaction temperature of step 2 is 20 to 85° C., preferably 40 to 80° C.;
[0027] As a further improvement of the present invention, including but not limited to, the reaction time of step 2 is 1 to 12 hours, preferably 3 to 10 hours;
[0028] In certain embodiments, after the reaction in step 2 is completed, the reaction solution is filtered, an aqueous sodium bicarbonate solution is added to slurry, filtered, and dried to obtain compound 4;
[0029] In certain embodiments, after the reaction in step 2 is completed, the reaction solution is filtered, 5% sodium bicarbonate aqueous solution is added for slurrying for 0.5 to 3 hours, filtered and dried to obtain compound 4.
[0030] The second aspect of the present invention provides a key intermediate impurity compound of formula 3 of tenegliptin, the structure of which is shown below:
[0031]
[0032] The third aspect of the present invention is the use of the compound of the tenegliptin impurity formula 4 in the preparation of a tenegliptin bulk drug or a tenegliptin hydrobromide bulk drug or an impurity reference substance of a pharmaceutical preparation composition containing the tenegliptin impurity.
[0033] Beneficial technical effects of the present invention:
[0034] 1. The inventors unexpectedly found through a large number of experimental screening that the reaction effect of step 1 of the present invention in water is significantly better than that in organic solvents. During the experiment, the inventors also found that when sodium hydroxide or potassium hydroxide is used in step 1, a large amount of by-products will be generated, and the reaction is very complicated. The method used in the present invention saves costs, is more environmentally friendly, and has good reproducibility, high yield, high purity, and is more conducive to the preparation of high-purity key intermediate impurity compound 4 of tilagliptin.
[0035] 2. The inventors found that the dealdehyde removal in hydrochloric acid ethanol solution is significantly better than other hydrochloric acid solutions or a combination of an organic solvent and hydrochloric acid. The method used in the present invention can achieve a yield of more than 95% and a purity of 99.5%.
[0036] 3. The present invention provides a method for synthesizing 1,4-bis(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine, a key intermediate impurity of tenegliptin. The inventors, through ingenious design, obtain the target product through substitution and dealdehydeation in two steps. The reaction steps are short, the yield is high, the purity is high, the reaction reagents are simple, the operation is simple, and it is environmentally friendly.
[0037] 4. The synthesized high-purity 1,4-di(3-methyl-1-phenyl-5-pyrazolyl)piperazine can be used as an impurity standard in the detection and analysis of the finished product of 1-(3-methyl-1-phenyl-5-pyrazolyl)piperazine, and can also be used as an impurity standard in the detection and analysis of the finished product of tenegliptin, thereby improving the accurate positioning and qualitative analysis of impurities in the detection and analysis of the finished products of 1-(3-methyl-1-phenyl-5-pyrazolyl)piperazine and tenegliptin, which is conducive to strengthening the control of the impurity, thereby improving the quality of the finished products of 1-(3-methyl-1-phenyl-5-pyrazolyl)piperazine and tenegliptin.
[0038] 5. The present invention fills the gap of the preparation method of the impurity at home and abroad. The provided method has cheap and easy-to-obtain raw materials, simple operation, low requirements for reaction equipment, mild reaction conditions, no special requirements, normal pressure operation, total yield of more than 80%, and HPLC purity ≥99%. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 This is the NMR spectrum of the compound of formula 3 obtained in Example 1 of the present invention;
[0040] Figure 2 This is the NMR spectrum of the compound of formula 4 obtained in Example 4 of the present invention;
[0041] Figure 3 This is the HPLC spectrum of the compound of formula 4 obtained in Example 4 of the present invention. DETAILED DESCRIPTION
[0042] The preparation method of the present invention will be described in further detail below in conjunction with specific examples. It should be understood that the following examples are only exemplary illustrations and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0043] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the reagents, materials, etc. used in the following examples, unless otherwise specified, can be obtained from commercial channels.
[0044] Embodiment 1:
[0045]
[0046] Water (100 mL) and potassium carbonate (25 g, 180.89 mmol, 3.4 eq) were added to the reaction kettle, and compound 1 (13 g, 53.65 mmol) and compound 2 (20 g, 90.64 mmol, 1.7 eq) were added. The temperature was raised to 95-105 ° C. and the reaction was carried out for 17 h. The reaction was completed by TLC detection. The temperature was lowered to 20-30 ° C. 100 mL of dichloromethane was added to the reaction system, and 1N aqueous hydrochloric acid solution was added to adjust the pH of the solution to 6-8. The solid was completely dissolved, and the mixture was allowed to stand for separation. Water was added to the organic phase to wash it once, and the mixture was allowed to stand for separation. The organic phase was concentrated to dryness to obtain a light yellow solid powder compound 3 (20.2 g, yield 88.3%) with a HPLC purity of 99.6%. The NMR spectrum is as follows: Figure 1 shown.
[0047] Embodiment 2-3
[0048] The preparation method of the compound of formula 3 is as described in Example 1, using sodium hydroxide or sodium carbonate instead of potassium carbonate, and the other reaction steps are consistent with Example 1. The different conditions and results are shown in Table 1 below:
[0049] Table 1
[0050]
[0051] Embodiment 4:
[0052]
[0053] 2M hydrogen chloride ethanol solution (200 mL) was added to the reaction kettle, and then compound 3 (20 g, 46.89 mmol) was added, the solution pH was 1-2, the temperature was raised to 50-60 ° C, the reaction was completed for 5 h, the reaction was controlled by TLC, and the filter cake was slurried for 1 h using 100 mL of 5% sodium bicarbonate, and then filtered. The filter cake was vacuum dried at 45 ° C to obtain an off-white solid (17.8 g, yield 95.3%), HPLC purity 99.5%, and the NMR spectrum was as follows Figure 2 As shown, the HPLC spectrum is as Figure 3 shown.
[0054] Embodiments 5 to 9
[0055] The preparation method of the compound of formula 4 is as described in Example 4, and the different conditions and results are shown in Table 2 below:
[0056] Table 2
[0057]
[0058] It can be seen from the above table that even at the same pH value, the reaction is quite different only because of the different solutions of the hydrochloric acid reagent used. It can be seen from the above table and Example 4 that the dealdehyde reaction reacts best in a hydrochloric acid ethanol solution.
[0059] In summary, it can be seen from Table 1 and Table 2 that by using the compounds of the structures shown in Formula 1 and Formula 2 as raw materials, using water as the reaction medium, and reacting by adding potassium carbonate to heat the reaction, and purifying the compound of the structure shown in Formula 3 generated by the reaction, a high yield can be obtained, and the correct structure of Formula 3 can be efficiently synthesized; the compound of the structure shown in Formula 3 is subjected to a dealdehyde reaction in a hydrogen chloride ethanol solution to obtain a compound of the structure shown in Formula 4, which is significantly better than a single hydrochloric acid solution, a methanol hydrogen chloride solution, an isopropanol hydrogen chloride solution, an ethyl acetate hydrogen chloride solution, and a concentrated hydrochloric acid n-butanol solution, and the synthesis method is simple to operate and has a high yield, which provides a cheap and readily available reference substance for the quality control of the tilagliptin bulk drug or the tilagliptin hydrobromide bulk drug or a pharmaceutical preparation composition containing them.
[0060] The experiments of Example 1 or 4 show that by selecting appropriate reaction medium, reaction conditions and reaction dosage, the structurally correct impurity formula 4 of tenegliptin can be efficiently synthesized. The synthesis method provided by the present invention is simple to operate, has a high yield, and has great commercial value and market prospects. In addition, the present invention provides the use of the tenegliptin impurity formula 4 synthesized according to the method in preparing a tenegliptin hydrobromide reference substance, which provides a qualified, inexpensive and readily available impurity reference substance for the quality control of the tenegliptin bulk drug or the tenegliptin hydrobromide bulk drug or a pharmaceutical preparation composition containing the same.
[0061] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a compound of the impurity formula 4 of tenegliptin, the reaction is as follows: The following steps are involved: Step 1: reacting a compound of formula 1 with a compound of formula 2 in the presence of potassium carbonate and water to obtain a compound of formula 3; Step 2: The compound of formula 3 is reacted in a hydrochloric acid ethanol solution to obtain a compound of formula 4.
2. The preparation method according to claim 1, characterized in that: In step 1, the molar ratio of the compound of formula 1 to the compound of formula 2 is 1:(1-3), preferably 1:(1.1-2.5).
3. The preparation method according to claim 1, characterized in that: The molar ratio of the compound of formula 1 to potassium carbonate in step 1 is 1:(1-5), preferably 1:(1.2-4).
4. The preparation method according to claim 1, characterized in that: The preparation method satisfies one or more of the following conditions: (1) The reaction temperature in step 1 is 80-110° C., preferably 85-110° C.; (2) The reaction time in step 1 is 5 to 24 hours, preferably 5 to 16 hours; (3) The volume of the aqueous solution in step 1 is 1 to 20 times, preferably 5 to 12 times, the mass of the compound of formula 1.
5. The preparation method according to any one of claims 1 to 4, characterized in that: After the reaction of step 1 is completed, the reaction solution is cooled to room temperature, and then an organic solvent and an acid are added, followed by extraction, separation, and concentration to dryness to obtain compound 3.
6. The preparation method according to claim 1, characterized in that: The molar ratio of hydrochloric acid in the hydrochloric acid ethanol solution of the compound of formula 3 in step 2 is 1:(1-20), preferably 1:(2-15).
7. The preparation method according to claim 1, characterized in that: The preparation method satisfies one or more of the following conditions: (1) The reaction temperature of step 2 is 20 to 85° C., preferably 40 to 80° C.; (2) The reaction time of step 2 is 1 to 12 hours, preferably 3 to 10 hours.
8. The preparation method according to any one of claims 1 to 4 or 6 or 7, characterized in that: After the reaction in step 2 is completed, the reaction solution is filtered, and a sodium bicarbonate aqueous solution is added for slurrying, filtering, and drying to obtain compound 4.
9. The compound of formula 3, the structure is shown below:
10. Use of the compound of the tenegliptin impurity formula 4 prepared by the preparation method according to any one of claims 1 to 4 or 6 or 7 in the preparation of tenegliptin bulk drug or tenegliptin hydrobromide bulk drug or impurity reference substance of pharmaceutical preparation compositions containing them.
